MedTrace Logo

Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study

NCT00686348 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2019-01-11

No results posted yet for this study

Summary

To assess the safety and effectiveness of Somatuline® Depot (lanreotide) Injection when administered by a health care professional (HCP), the patient, the patient's partner or parent/guardian as part of their routine acromegaly care.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen (formerly Tercica, Inc.)

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00686348 on ClinicalTrials.gov